We are live on ! Find out more
Citadel Advisors

Citadel Advisors Portfolio holdings

AUM $618B
1-Year Est. Return 30.34%
 

Citadel Advisors, founded in 1990 by Kenneth C. Griffin as Citadel LLC and headquartered in Chicago, Illinois, is one of the world’s most prominent hedge funds, managing tens of billions in assets through sophisticated quantitative trading strategies. The firm excels in market-making and high-frequency trading across asset classes like equities, fixed income, options, and commodities, leveraging cutting-edge technology and data analysis to generate returns. Citadel operates two main arms: its hedge fund business, which serves institutional and high-net-worth investors, and Citadel Securities, a leading market maker that facilitates a significant portion of U.S. equity and options trades. Known for its secretive, high-performance culture, Citadel has grown into a financial titan under Griffin’s leadership, influencing global markets with its scale and innovation.

This Fund
S&P 500
This Quarter Est. Return
+6.7%
1 Year Est. Return
+30.34%
3 Year Est. Return
+94.87%
5 Year Est. Return
+105.94%
10 Year Est. Return
+433.28%
AUM
$164B
AUM Growth
+$34B
Cap. Flow
+$21.1B
Cap. Flow %
12.82%
Top 10 Hldgs %
19.02%
Holding
8,908
New
1,440
Increased
3,569
Reduced
2,696
Closed
989

Sector Composition

Rank Sector Weight
1 Technology 6.08%
2 Financials 6.03%
3 Industrials 5.01%
4 Consumer Discretionary 4.73%
5 Healthcare 4.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
KND
7151
CALL
DELISTED
Kindred Healthcare
KND
$136K ﹤0.01%
14,000
-8,200
-37% -$61K
NHA
7152
DELISTED
Nuveen Municipal 2021 Target Term Fund
NHA
$135K ﹤0.01%
+14,293
New +$138K
NNC
7153
DELISTED
Nuveen North Carolina Quality Municipal Income Fund
NNC
$135K ﹤0.01%
+10,455
New +$137K
AVDL
7154
PUT
DELISTED
Avadel Pharmaceuticals
AVDL
$134K ﹤0.01%
16,400
+4,900
+43% +$46K
DLNG icon
7155
CALL
Dynagas LNG Partners
DLNG
$135M
$134K ﹤0.01%
12,300
+900
+8% +$11.6K
QUIK icon
7156
QuickLogic
QUIK
$238M
$134K ﹤0.01%
5,482
-473
-8% -$10.7K
JCO
7157
DELISTED
Nuveen Credit Opportunities 2022 Target Term Fund
JCO
$134K ﹤0.01%
+14,125
New +$140K
SFUN
7158
CALL
DELISTED
Fang Holdings Limited American Depositary Shares (each representing ten Class A Ordinary Shares)
SFUN
$134K ﹤0.01%
482
-66
-12% -$14.9K
ALDR
7159
CALL
DELISTED
Alder Biopharmaceuticals
ALDR
$134K ﹤0.01%
11,700
-4,300
-27% -$48K
HTGC icon
7160
PUT
Hercules Capital
HTGC
$3.15B
$133K ﹤0.01%
+10,100
New +$132K
IHTA
7161
DELISTED
Invesco High Income 2024 Target Term Fund
IHTA
$131K ﹤0.01%
+12,667
New +$127K
CRBP icon
7162
Corbus Pharmaceuticals
CRBP
$165M
$130K ﹤0.01%
+612
New +$131K
LABD icon
7163
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$70.2M
$130K ﹤0.01%
+14
New +$139K
MUFG icon
7164
Mitsubishi UFJ Financial
MUFG
$254B
$130K ﹤0.01%
17,826
-31,678
-64% -$216K
TEF
7165
DELISTED
Telefonica
TEF
$130K ﹤0.01%
16,560
-13,105
-44% -$108K
CRBP icon
7166
PUT
Corbus Pharmaceuticals
CRBP
$165M
$129K ﹤0.01%
+607
New +$130K
GGB icon
7167
Gerdau
GGB
$9.93B
$129K ﹤0.01%
43,675
+9,412
+27% +$25.6K
HMY icon
7168
CALL
Harmony Gold Mining
HMY
$10.3B
$129K ﹤0.01%
68,800
+600
+0.9% +$1.07K
LPCN icon
7169
CALL
Lipocine
LPCN
$17.4M
$129K ﹤0.01%
2,200
+329
+18% +$20.5K
GST
7170
DELISTED
Gastar Exploration Inc.
GST
$129K ﹤0.01%
+122,959
New +$107K
SIGM
7171
CALL
DELISTED
Sigma Designs Inc
SIGM
$129K ﹤0.01%
18,500
+2,200
+13% +$13.8K
LXRX icon
7172
PUT
Lexicon Pharmaceuticals
LXRX
$1.03B
$128K ﹤0.01%
13,000
-3,000
-19% -$31.2K
PBT
7173
CALL
Permian Basin Royalty Trust
PBT
$1.41B
$128K ﹤0.01%
14,400
-11,100
-44% -$102K
AXAS
7174
DELISTED
Abraxas Petroleum Corp
AXAS
$128K ﹤0.01%
+2,598
New +$108K
COOP
7175
DELISTED
Mr. Cooper
COOP
$127K ﹤0.01%
12,474
+8,681
+229% +$83.5K

Similar funds

Citadel Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Citadel Advisors held 8,908 positions worth $164B, up 26% from $130B the previous quarter. Its ten largest holdings account for 19% of the portfolio.

Citadel Advisors deployed $21.1B of net new capital in Q4 2017, opening 1,440 new positions and adding to 3,569 existing holdings. Its largest new stake was Celgene Corp: 3,708,916 shares worth $387M.

By sector, the portfolio is most concentrated in Technology at 6.1% of assets, down from 7% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Goldman Sachs, an estimated $441M trimmed.

  • Citadel Advisors's largest Q4 2017 buy was Celgene Corp: 3,708,916 shares worth $387M.
  • Citadel Advisors added most to State Street SPDR S&P 500 ETF Trust in Q4 2017, an estimated $1.16B increase.
  • Citadel Advisors's biggest Q4 2017 reduction was Goldman Sachs, cutting an estimated $441M.
  • Citadel Advisors fully exited CR Bard Inc. in Q4 2017, selling an estimated $209M.
  • Citadel Advisors's ten largest holdings make up 19% of its $164B portfolio in Q4 2017.
  • Citadel Advisors opened 1,440 new positions and closed 989 in Q4 2017.
  • Citadel Advisors's portfolio value rose 26% quarter-over-quarter to $164B.

Based on Citadel Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.